Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 5/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415553 | 0.82 | PLAT (0.42) | PLATADORA3ALDH1A1KDM4EMAPT | |
| SCHEMBL24834915 | 0.79 | PLAT (0.35) | PLAT | |
| SCHEMBL24835026 | 0.79 | PLAT (0.37) | PLATADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL24835445 | 0.79 | PLAT (0.38) | PLATADORA3ALDH1A1KDM4EMAPT | |
| SCHEMBL24834879 | 0.77 | PLAT (0.37) | PLATADORA3ALDH1A1KDM4EMAPT | |
| SCHEMBL24835012 | 0.77 | PLAT (0.44) | PLATALDH1A1MAPT | |
| SCHEMBL30172844 | 0.72 | PLAT (0.39) | PLATADORA3ALDH1A1KDM4EPOLB | |
| SCHEMBL29785667 | 0.72 | PLAT (0.39) | PLATADORA3ALDH1A1KDM4EPOLB | |
| SCHEMBL24835003 | 0.72 | PLAT (0.39) | PLATADORA3ALDH1A1KDM4EPOLB | |
| SCHEMBL30172846 | 0.72 | PLAT (0.39) | PLATADORA3ALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | PLAT 3745/4885ADORA3 4838/4885ALDH1A1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.